0.00 - 0.01
0.00 - 0.02
1.30M / 496.9K (Avg.)
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-4.76%
Negative revenue growth while LBL.AX stands at 8.36%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
1.59%
Gross profit growth under 50% of LBL.AX's 5.71%. Michael Burry would be concerned about a severe competitive disadvantage.
59.24%
Positive EBIT growth while LBL.AX is negative. John Neff might see a substantial edge in operational management.
59.24%
Positive operating income growth while LBL.AX is negative. John Neff might view this as a competitive edge in operations.
-96.52%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.93%
Share reduction more than 1.5x LBL.AX's 17.62%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
1.93%
Diluted share reduction more than 1.5x LBL.AX's 17.62%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
97.84%
OCF growth of 97.84% while LBL.AX is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
69.41%
Positive FCF growth while LBL.AX is negative. John Neff would see a strong competitive edge in net cash generation.
-90.53%
Negative 10Y revenue/share CAGR while LBL.AX stands at 207.04%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-56.69%
Negative 5Y CAGR while LBL.AX stands at 207.04%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-57.18%
Negative 3Y CAGR while LBL.AX stands at 28.50%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-100.04%
Negative 10Y OCF/share CAGR while LBL.AX stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
99.83%
OCF/share CAGR of 99.83% while LBL.AX is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
-100.40%
Negative 3Y OCF/share CAGR while LBL.AX stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-99.95%
Negative 10Y net income/share CAGR while LBL.AX is at 255.78%. Joel Greenblatt sees a major red flag in long-term profit erosion.
100.07%
Below 50% of LBL.AX's 255.78%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
100.31%
Below 50% of LBL.AX's 235.42%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.30%
We increase R&D while LBL.AX cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-15.35%
We cut SG&A while LBL.AX invests at 7.67%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.